/

Allena Pharmaceuticals, Inc.

ALNAQ US

ALNAQ USAllena Pharmaceuticals, Inc.

United States Composite

0.00

USD

+0.00

(+400.00%)

Next Earnings

August 11

Held by Insiders

0.92%

Held by Institutions

- -

Short % of Float

8.47%

YTD Yield

150.00%

3Y Yield

-99.96%

Capital Structure

FRC

•

in mil. unless spec.

ST Debt

LT Borrowings

LT Finance Leases

Preferred Equity and Hybrid Capital

Shares Outstanding

Market Capitalization

Working Capital

FRC

•

in mil. unless spec.

Total Current Assets

Cash, Cash Equivalents & STI

Accounts Receivable, Net

Inventories

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

- -

Net Income, GAAP

- -

Free Cash Flow

- -

Total Cash Common Dividend

- -

Total Equity

- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

-Infinity

- -

-Infinity

- -

-Infinity

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

-Infinity

- -

-Infinity

- -

-Infinity

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

-Infinity

- -

-Infinity

- -

-Infinity

- -

Company Description

Full Time Employees: 12
Sector: Healthcare
Industry: Biotechnology
Address: One Newton Executive Park Newton MA United States 02462
IPO Date: Nov 2, 2017
CIK: 0001624658
Website: www.allenapharma.com
Business: Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on May 18, 2023.

Company Description

Full Time Employees: 12
Sector: Healthcare
Industry: Biotechnology
Address: One Newton Executive Park Newton MA United States 02462
IPO Date: Nov 2, 2017
CIK: 0001624658
Website: www.allenapharma.com
Business: Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on May 18, 2023.